Jane Street Group LLC Lowers Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Jane Street Group LLC cut its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 50.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,606 shares of the medical instruments supplier’s stock after selling 15,613 shares during the quarter. Jane Street Group LLC’s holdings in LeMaitre Vascular were worth $1,450,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in LMAT. Driehaus Capital Management LLC increased its position in LeMaitre Vascular by 52.2% in the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock valued at $21,740,000 after acquiring an additional 90,573 shares during the period. Nicholas Investment Partners LP acquired a new stake in LeMaitre Vascular during the 2nd quarter worth approximately $3,900,000. Conestoga Capital Advisors LLC grew its stake in shares of LeMaitre Vascular by 1.9% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock valued at $183,769,000 after purchasing an additional 36,850 shares during the last quarter. Rice Hall James & Associates LLC increased its holdings in shares of LeMaitre Vascular by 15.7% in the third quarter. Rice Hall James & Associates LLC now owns 261,306 shares of the medical instruments supplier’s stock valued at $24,273,000 after purchasing an additional 35,383 shares during the period. Finally, F M Investments LLC raised its stake in shares of LeMaitre Vascular by 36.6% during the third quarter. F M Investments LLC now owns 123,545 shares of the medical instruments supplier’s stock worth $11,476,000 after purchasing an additional 33,087 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on LMAT shares. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Oppenheimer restated an “outperform” rating and issued a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Barrington Research boosted their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Finally, Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target for the company. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Price Performance

NASDAQ LMAT opened at $92.84 on Friday. The business has a 50 day moving average price of $97.93 and a 200 day moving average price of $90.42. The company has a market capitalization of $2.09 billion, a P/E ratio of 50.73, a PEG ratio of 2.47 and a beta of 0.93. LeMaitre Vascular, Inc. has a 1-year low of $52.88 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same quarter in the prior year, the company earned $0.33 earnings per share. LeMaitre Vascular’s revenue was up 15.6% compared to the same quarter last year. On average, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.69%. The ex-dividend date was Thursday, November 21st. LeMaitre Vascular’s payout ratio is 34.97%.

Insiders Place Their Bets

In other news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares in the company, valued at $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 10.79% of the stock is currently owned by company insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.